Paronychia in association with indinavir treatment

Clin Infect Dis. 2001 Jan;32(1):140-3. doi: 10.1086/317546.

Abstract

To assess a possible association between antiretroviral treatment and paronychia, we conducted a retrospective cohort study of 288 human immunodeficiency virus-positive protease inhibitor recipients. Indinavir treatment-adjusted for age, sex, CD4 count, diabetes status and other antiretroviral drug exposures-was significantly associated with paronychia of the great toe (hazard ratio 4.7; 95% confidence interval 1.6-13.9).

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV Protease Inhibitors / adverse effects*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1*
  • Humans
  • Indinavir / adverse effects*
  • Indinavir / therapeutic use
  • Male
  • Middle Aged
  • Paronychia / chemically induced*
  • Paronychia / complications
  • Retrospective Studies
  • Viral Load

Substances

  • HIV Protease Inhibitors
  • Indinavir